YieldMax MRNA Option Income Strategy ETF(MRNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MRNY YieldMax MRNA Option Income Strategy ETF

Pre-Mkt 04-14 06:27:35 EDT

17.82

-0.07

-0.39%

盘前18.20

+0.38+2.13%

06:17 EDT

High18.45	Low17.82	Vol177.99K
Open17.96	D1 Closing17.89	Amplitude3.52%
Mkt Cap122.60M	Tradable Cap122.60M	Total Shares6.88M
T/O3.21M	T/O Rate2.59%	Tradable Shares6.88M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MRNY","market":"US","secType":"STK","nameCN":"YieldMax MRNA Option Income Strategy ETF","latestPrice":17.82,"timestamp":1776110400000,"preClose":17.89,"halted":0,"volume":177991,"hourTrading":{"tag":"盘前","latestPrice":18.2,"preClose":17.82,"latestTime":"06:17 EDT","volume":664,"amount":11965.156496,"timestamp":1776161846648,"change":0.38,"changeRate":0.021324,"amplitude":0.016801},"delay":0,"changeRate":-0.0039128004471772095,"floatShares":6879974,"shares":6879974,"eps":0,"marketStatus":"Pre-Mkt","change":-0.07,"latestTime":"04-14 06:27:35 EDT","open":17.96,"high":18.45,"low":17.8199,"amount":3209659.551637,"amplitude":0.035221,"askPrice":18.08,"askSize":142,"bidPrice":17.93,"bidSize":250,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1776173400000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":17.82,"sharesOutstanding":6479974,"nav":18.17,"aum":125009127.58,"dividendRate":0.942372,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":18.2,"preClose":17.82,"latestTime":"06:17 EDT","volume":664,"amount":11965.156496,"timestamp":1776161846648,"change":0.38,"changeRate":0.021324,"amplitude":0.016801},"postHourTrading":{"tag":"盘后","latestPrice":18.2573,"preClose":17.82,"latestTime":"19:59 EDT","volume":2554,"amount":45942.7824,"timestamp":1776124756208,"change":0.4373,"changeRate":0.02454,"amplitude":0.02454},"volumeRatio":1.343662720713443,"impliedVol":0.3614,"impliedVolPercentile":0.2742},"requestUrl":"/m/hq/s/MRNY/tweets","defaultTab":"tweets","newsList":[{"id":"2627413278","title":"U.S. RESEARCH ROUNDUP-Biogen, Equinix, Revolution Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2627413278","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627413278?lang=en_us&edition=fundamental","pubTime":"2026-04-14 15:45","pubTimestamp":1776152709,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Biogen, Equinix, Revolution MedicinesApril 14 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Biog","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nL4N40X0LT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSFU","MSFL","MAA","MSFT","GH","MRNX","MSFO","ADPT","CBRE","BEX","MSFD","BSX","MSFX","BL","SJM","CAG","TREE","NSA","NTRA","INSP","CPT","AVB","JAN","BIIB","MRNY","BEZ","PODD","HSY","DLR","EXR","FLS","LNG","CAI","MRNA","BRBR","BDX","GIS","HUBS","IDYA","ASAN","KHC","MKC","NEO","WGS","CPB","ADGM","BE","CUBE","EQIX","BEG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627469126","title":"Trump officials consider ophthalmologist Hemmati for top vaccine post, reports say","url":"https://stock-news.laohu8.com/highlight/detail?id=2627469126","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627469126?lang=en_us&edition=fundamental","pubTime":"2026-04-14 06:14","pubTimestamp":1776118462,"startTime":"0","endTime":"0","summary":"UPDATE 1-Trump officials consider ophthalmologist Hemmati for top vaccine post, reports sayCredits Endpoints News with reporting the news first in paragraph 2, adds official comment in 3, background in 4-5. WASHINGTON, April 13  - The Trump administration is considering appointing Houman Hemmati, an ophthalmologist and a frequent Fox News guest, to lead the FDA's Center for Biologics Evaluation and Research, according to media reports.The news was first reported on Monday by Endpoints News. The Washington Post also reported that Hemmati was being considered, citing three people familiar with the matter.\"No decision has been made on the selection of the next CBER director. We continue to vet highly qualified candidates,\" said Department of Health and Human Services spokesperson Andrew Nixon.at the end of the month. FDA Commissioner Marty Makary said a replacement would be named before his departure.Prasad, an oncologist, was an outspoken critic of U.S. drug and vaccine policies, particu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nL1N40W13L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4501","MRNX","MRNY","BK4139","BK4585","BK4588","BK4568","BK4534","BK4532","BK4533","BK4551","MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627830468","title":"Bullish flow in Moderna with shares up 1.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627830468","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627830468?lang=en_us&edition=fundamental","pubTime":"2026-04-14 02:35","pubTimestamp":1776105313,"startTime":"0","endTime":"0","summary":"Bullish flow in Moderna (MRNA), with shares up 56c, or 1.11%, near $51.52. Options volume relatively light with 19k contracts traded and calls lead...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bullish-flow-in-moderna-with-shares-up-1-11-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bullish-flow-in-moderna-with-shares-up-1-11-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNX","BK4139","BK4548","BK4551","BK4588","BLSG","BLSX","BK4533","MRNA","BK4532","BK4568","BK4112","BK4501","MRNY","BK4534","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627431812","title":"OS Therapies appoints Moderna co-founder Robert Langer as strategic advisor","url":"https://stock-news.laohu8.com/highlight/detail?id=2627431812","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627431812?lang=en_us&edition=fundamental","pubTime":"2026-04-13 18:02","pubTimestamp":1776074546,"startTime":"0","endTime":"0","summary":"OS Therapies appointed Robert “Bob” S. Langer to its strategic advisory board.Langer is an MIT Institute Professor who co-founded Moderna.He will advise on prioritizing OS Therapies’ listeria-oncology pipeline.Mandate includes evaluating combinations with other oncology technologies.Scope also covers selection of tunable antibody-drug conjugate candidates for further development.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL4ywHk8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","BK4551","BK4588","MRNA","MRNX","BK4568","MRNY","BK4534","BK4501","OSTX","BK4532","BK4139","BK4548","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626151214","title":"Is Moderna (MRNA) Priced Too High After A 66% Year To Date Rally?","url":"https://stock-news.laohu8.com/highlight/detail?id=2626151214","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626151214?lang=en_us&edition=fundamental","pubTime":"2026-04-10 07:32","pubTimestamp":1775777541,"startTime":"0","endTime":"0","summary":"Investors may be wondering whether Moderna's share price still makes sense after recent swings, or if the value case has already played out.\nModerna closed at US$51.28, with returns of 4.2% over 7 days, a 6.7% decline over 30 days, a 66.2% gain year to date, and a 109.3% gain over 1 year, while 3 and 5 year returns sit at 68.1% and 67.9% declines.\nThese moves have put fresh attention on how the market is currently pricing Moderna and whether recent momentum aligns with the underlying...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/128680956-main-header/1756229826628","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/128680956-main-header/1756229826628"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/is-moderna-mrna-priced-too-high-after-a-66-year-to-date-rall","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/is-moderna-mrna-priced-too-high-after-a-66-year-to-date-rall","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4568","BK4501","DCF","BK4532","BK4533","BK4585","MRNY","MRNA","BK4534","BK4548","MRNX","BK4551","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626907798","title":"US Cdc Delays Publishing Report Showing Covid Vaccine Benefits - Washington Post","url":"https://stock-news.laohu8.com/highlight/detail?id=2626907798","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626907798?lang=en_us&edition=fundamental","pubTime":"2026-04-09 17:02","pubTimestamp":1775725374,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nFWN40R1IM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4548","LU0321505868.SGD","BK4592","IE00B19Z3581.USD","BK4501","BK4533","LU0234572021.USD","BK4588","IE00B19Z3B42.SGD","LU1066053197.SGD","LU0289739699.SGD","LU1066051498.USD","LU0306807586.USD","BK4568","BK4581","BK4585","LU0321505439.SGD","LU0225771236.USD","BK4599","LU1057294990.SGD","LU0170899867.USD","BK4139","LU0058720904.USD","LU0985481810.HKD","BK4007","SG9999001176.SGD","SG9999002224.SGD","SG9999003800.SGD","BK4551","LU0306806265.USD","LU0122379950.USD","LU1883839398.USD","MRNY","LU0225284248.USD","LU1894683348.USD","MRNA","LU1894683264.USD","IE00BLSP4452.SGD","BK4534","SG9999011175.SGD","BK4532","LU1023059063.AUD","MRNX","SG9999002232.USD","SG9999001176.USD","SGXZ57979304.SGD","LU0868494617.USD","IE000M9KFDE8.USD","IE00BBT3K403.USD","SG9999013999.USD","IE0002270589.USD","BK4547","IE00BLSP4239.USD","LU0456855351.SGD","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625194943","title":"Moderna Flu And RSV Data Highlight Progress Toward Repeat Vaccination Business","url":"https://stock-news.laohu8.com/highlight/detail?id=2625194943","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625194943?lang=en_us&edition=fundamental","pubTime":"2026-04-08 19:29","pubTimestamp":1775647747,"startTime":"0","endTime":"0","summary":"Moderna (NasdaqGS:MRNA) will present late breaking Phase 3 data on its mRNA-1010 flu vaccine and mRESVIA RSV vaccine at the 2026 European Society of Clinical Microbiology and Infectious Diseases Congress.\nInterim results show strong immune response in individuals who received repeat doses of these vaccines.\nThe data set includes information on immune response and tolerability in revaccinated participants.\n\nFor Moderna, known widely for its COVID-19 vaccine, these new mRNA-1010 and mRESVIA...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/128680956-main-header/1756229826628","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/128680956-main-header/1756229826628"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/moderna-flu-and-rsv-data-highlight-progress-toward-repeat-va","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/moderna-flu-and-rsv-data-highlight-progress-toward-repeat-va","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065732104.USD","BK4585","BK4588","BK4548","BK4501","PRGS","MRNA","BK4139","BK4533","MRNX","BK4551","BK4568","BK4534","BK4097","MRNY","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625952342","title":"Mixed options sentiment in Moderna with shares down 1.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625952342","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625952342?lang=en_us&edition=fundamental","pubTime":"2026-04-07 23:41","pubTimestamp":1775576470,"startTime":"0","endTime":"0","summary":"Mixed options sentiment in Moderna (MRNA), with shares down 60c near $48.17. Options volume relatively light with 5407 contracts traded and calls l...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mixed-options-sentiment-in-moderna-with-shares-down-1-23-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mixed-options-sentiment-in-moderna-with-shares-down-1-23-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","MRNA","MRNY","BK4139","BK4532","BK4585","BK4568","BK4548","BK4533","BK4588","BK4534","BK4501","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625537339","title":"RBC Adjusts Price Target on Moderna to $35 From $30, Maintains Sector Perform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2625537339","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625537339?lang=en_us&edition=fundamental","pubTime":"2026-04-07 21:05","pubTimestamp":1775567104,"startTime":"0","endTime":"0","summary":"Moderna (MRNA) has an average rating of hold and mean price target of $44.21, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4533","BK4548","MRNA","MRNX","MRNY","BK4532","BK4551","BK4588","BK4501","BK4585","BK4534","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625602719","title":"Moderna says mRNA-1010 flu shot shows similar immune response on revaccination in older adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2625602719","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625602719?lang=en_us&edition=fundamental","pubTime":"2026-04-07 06:07","pubTimestamp":1775513243,"startTime":"0","endTime":"0","summary":"Moderna scheduled late-breaking presentations at ESCMID Global Congress in Munich on April 18 covering revaccination data for investigational seasonal flu shot mRNA-1010 and RSV vaccine mRESVIA.Flu revaccination analysis in adults 50 and older showed immune responses held up across prior vaccine histories, with no new safety issues reported.Interim Phase 3 data for mRESVIA as a booster in adults 60 and older previously given a protein-based RSV vaccine indicated it was well tolerated, with responses consistent with restoring protection.Regulatory reviews for mRNA-1010 are underway in US, Europe, Canada, Australia, with first potential approvals expected in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL50ZPzx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNX","BK4568","MRNA","BK4139","BK4534","BK4551","BK4533","BK4548","MRNY","BK4588","BK4585","BK4532","BK4501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625564048","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Rocket Pharmaceuticals (RCKT) and Moderna (MRNA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2625564048","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625564048?lang=en_us&edition=fundamental","pubTime":"2026-04-06 02:20","pubTimestamp":1775413205,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Rocket Pharmaceuticals (RCKT) and Moderna (MRNA). Rocket Pharmace...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-rocket-pharmaceuticals-rckt-and-moderna-mrna-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-rocket-pharmaceuticals-rckt-and-moderna-mrna-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","BK4588","MRNX","BK4585","XLV","MRNA","BK4532","BK4501","BK4568","BK4581","BK4548","BK4137","RCKT","XBI","BK4533","HCSG","LU0029874061.USD","LABU","BK4551","MRNY","BK4139","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624523666","title":"Moderna Advances Phase 3 H5 Bird Flu Shot, Expanding Its Pandemic Vaccine Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2624523666","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624523666?lang=en_us&edition=fundamental","pubTime":"2026-04-04 00:33","pubTimestamp":1775233983,"startTime":"0","endTime":"0","summary":"Moderna ($MRNA) announced an update on their ongoing clinical study. Moderna (MRNA) is advancing a large Phase 3 study called “A Study of mRNA-1018...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/moderna-advances-phase-3-h5-bird-flu-shot-expanding-its-pandemic-vaccine-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/moderna-advances-phase-3-h5-bird-flu-shot-expanding-its-pandemic-vaccine-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4548","BK4501","MRNA","BK4139","BK4533","MRNX","BK4551","BK4568","BK4534","BK4585","MRNY","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624502803","title":"Moderna Is Maintained at Equal-Weight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2624502803","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624502803?lang=en_us&edition=fundamental","pubTime":"2026-04-02 21:49","pubTimestamp":1775137740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MRNA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 02, 2026 09:49 ET (13:49 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4548","MRNA","BK4534","MRNX","BK4501","BK4568","BK4585","BK4588","MRNY","BK4532","BK4533","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624514224","title":"Barclays Adjusts Price Target on Moderna to $48 From $25, Maintains Equalweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2624514224","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624514224?lang=en_us&edition=fundamental","pubTime":"2026-04-01 21:54","pubTimestamp":1775051640,"startTime":"0","endTime":"0","summary":"Moderna (MRNA) has an average rating of hold and mean price target of $43.95, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4501","BK4588","BK4534","MRNY","BK4585","BK4532","MRNX","MRNA","BK4533","BK4568","BK4139","BK4548","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624734516","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Palisade Bio (PALI) and Moderna (MRNA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624734516","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624734516?lang=en_us&edition=fundamental","pubTime":"2026-04-01 21:00","pubTimestamp":1775048452,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Palisade Bio (PALI) and Moderna (MRNA). Palisade Bio (PALI) In a ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-palisade-bio-pali-and-moderna-mrna-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-palisade-bio-pali-and-moderna-mrna-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNA","PALI","LU0128526141.USD","XBI","MRNX","BK4588","BK4533","XLV","BK4534","BK4581","BK4585","LABU","BK4501","LU0029874061.USD","BK4548","BK4137","BK4532","MRNY","BK4007","BK4551","BK4568","HCSG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624515697","title":"Rare disease advocacy group urges Trump administration to restore FDA clarity","url":"https://stock-news.laohu8.com/highlight/detail?id=2624515697","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624515697?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:30","pubTimestamp":1775046600,"startTime":"0","endTime":"0","summary":"Rare disease advocacy group urges Trump administration to restore FDA clarityLetter sent to President Trump, Health Secretary Kennedy, Medicare Chief Oz, and FDA Commissioner MakaryCoalition cites FDA","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nL4N40K0VU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4533","BK4548","MRNA","MRNX","MRNY","BK4532","BK4551","BK4588","BK4501","BK4585","BK4534","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624531204","title":"Option traders moderately bearish in Moderna with shares up 3.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624531204","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624531204?lang=en_us&edition=fundamental","pubTime":"2026-04-01 01:45","pubTimestamp":1774979114,"startTime":"0","endTime":"0","summary":"Option traders moderately bearish in Moderna (MRNA), with shares up $1.78, or 3.7%, near $50.02. Options volume relatively light with 15k contracts...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/option-traders-moderately-bearish-in-moderna-with-shares-up-3-7-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/option-traders-moderately-bearish-in-moderna-with-shares-up-3-7-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MRNA","BK4534","MRNX","BK4501","BK4585","BK4533","BK4588","BK4532","MRNY","BK4568","BK4548","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622808488","title":"Moderna Inc. Stock Sheds 7.5%, Underperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2622808488","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622808488?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:32","pubTimestamp":1774643520,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. shed 7.5% to $49.56 on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index falling 2.1% to 20,948.36 and Dow Jones Industrial Average falling 1.7% to 45,166.64.The stock's fall snapped a three-day winning streak.Moderna Inc. closed 16.8% short of its 52-week high of $59.55, which the company achieved on March 4th.The stock underperformed when compared to some of its peers, as Johnson & Johnson rose 0.5% to $240.45, Pfizer Inc. fell 1.9% to $27.04, and Gilead Sciences Inc. fell 1.92% to $134.25.Trading volume totaled 7.0 million, compared to the 50-day average of 11.1 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","MRNA","MRNY","BK4139","BK4532","BK4585","BK4568","BK4548","BK4533","BK4588","BK4534","BK4501","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622876141","title":"BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT","url":"https://stock-news.laohu8.com/highlight/detail?id=2622876141","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622876141?lang=en_us&edition=fundamental","pubTime":"2026-03-28 00:00","pubTimestamp":1774627219,"startTime":"0","endTime":"0","summary":"BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDTS&P 500 .SPXTop PerformersPercent ChangeEntergy Corp ETR.N+7.8%Brown-Forman Corp BFb.N+5.6%Campbell's Co CPB.OQ+5.0%Vistra Corp VST.N+4.8%EchoStar Corp SATS.OQ+4.3%Bottom PerformersPercent ChangeDatadog Inc DDOG.OQ-6.4%Coinbase Global Inc COIN.OQ-6.0%Align Technology Inc ALGN.OQ-5.4%Dexcom Inc DXCM.OQ-5.3%Moderna Inc MRNA.OQ-5.2%As of 12:00 p.m., the S&P 500 .SPX lost 49.51 points, or 0.76%, to 6,427.65 and had posted 22 new 52-week highs and 16 new lows.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F1J8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","LU0320765489.SGD","LU1861558580.USD","MRNX","IE00B19Z3581.USD","BK4585","LU1720051017.SGD","LU0208291251.USD","LU1548497426.USD","LU2106854487.HKD","BK4089","IE00BMG7P702.HKD","IE00BMG7P587.USD","BK4600","LU1917777945.USD","IE00BMPRXN33.USD","BK4533","LU2264538146.SGD","IE00BMPRXR70.SGD","COIA","LU2362541513.USD","BK4212","IE00BMG7P926.USD","DOGD","LU2362541273.HKD","BK4504","BK4539","LU1974910355.USD","COIO","BK4606","BK4532","LU1064131342.USD","SATG","CONY","LU1323610961.USD","BK4501","VSTL","LU2125909247.SGD","BK4613","LU2357305700.SGD","BK4607","LU0266013472.USD","LU2023250843.SGD","IE00BMG7P819.SGD","BK4100","COYY","LU1988902786.USD","IE00BD4GTW91.USD","LU2362540622.SGD","IE00BMQBXF63.USD","BK4528","IE00B7SZLL34.SGD","BK4082","IE00BFMHRM44.USD","BK4595","BK4596","BK4588","FIAT","COIW","BK4112","LU2211815571.USD","LU1861559042.SGD","LU1923622614.USD","BK4568","ICOI","BK4548","IE00BD4GTT62.SGD","CONI","IE0002270589.USD","LU2210150020.SGD","LU1861217088.USD","LU2148611432.USD","LU1861220207.SGD","LU2433249047.HKD","BK4023","IE00BZ18W340.USD","LU1093756325.SGD","LU0354030511.USD","BK4551","MRNY","BK4139","BK4561","IE00B19Z3B42.SGD","LU2095319765.USD","CONX","LU0354030438.USD","LU2023250504.SGD","BK4534","BK4081","LU1720051108.HKD","LU2286300806.USD","IE00BZ18W456.USD","LU2210149790.SGD","BK4516","BK4535","IE00BD4GTV84.USD","COIG","LU0170899867.USD","BK4554","LU2125909593.SGD","IE00BMG7P694.USD","LU2360107671.USD","LU0070302665.USD","BK4198","COII","BK4105"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622895399","title":"Is Moderna (MRNA) Attractive After A 73% Year To Date Share Price Jump?","url":"https://stock-news.laohu8.com/highlight/detail?id=2622895399","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622895399?lang=en_us&edition=fundamental","pubTime":"2026-03-27 01:15","pubTimestamp":1774545313,"startTime":"0","endTime":"0","summary":"Wondering if Moderna at US$53.54 is a bargain or a value trap? This article walks through what the numbers are really saying about the stock.\nThe share price return sits at 2.2% over 7 days, 6.5% over 30 days, 73.5% year to date and 70.1% over the last year, alongside a 64.0% decline over 3 years and a 59.1% decline over 5 years.\nRecent headlines around Moderna have focused on its position in the pharmaceutical and biotech space and how investors are reassessing companies in this part of the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/128680956-main-header/1756229826628","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/128680956-main-header/1756229826628"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/is-moderna-mrna-attractive-after-a-73-year-to-date-share-pri","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/is-moderna-mrna-attractive-after-a-73-year-to-date-share-pri","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4551","MRNA","BK4533","BK4211","BK4588","BK4532","BK4534","BK4548","MRNX","MRNY","FCF","BK4568","BK4139","BK4585","DCF","BK4501"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0073},{"period":"1month","weight":-0.0805},{"period":"3month","weight":-0.0257},{"period":"6month","weight":0.0241},{"period":"1year","weight":-0.3146},{"period":"ytd","weight":0.2122}],"compareEarnings":[{"period":"1week","weight":0.0412},{"period":"1month","weight":0.036},{"period":"3month","weight":-0.0111},{"period":"6month","weight":0.0315},{"period":"1year","weight":0.285},{"period":"ytd","weight":0.0061}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"The fund advisor will seek to employ the fund's investment strategy as the fund relates to MRNA regardless of whether there are periods of adverse market, economic, or other conditions and will not seek to take temporary defensive positions during such periods. The fund is non-diversified.","exchange":"ARCA","name":"YieldMax MRNA Option Income Strategy ETF","nameEN":"YieldMax MRNA Option Income Strategy ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"YieldMax MRNA Option Income Strategy ETF(MRNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest YieldMax MRNA Option Income Strategy ETF(MRNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"YieldMax MRNA Option Income Strategy ETF,MRNY,YieldMax MRNA Option Income Strategy ETF股票,YieldMax MRNA Option Income Strategy ETF股票老虎,YieldMax MRNA Option Income Strategy ETF股票老虎国际,YieldMax MRNA Option Income Strategy ETF行情,YieldMax MRNA Option Income Strategy ETF股票行情,YieldMax MRNA Option Income Strategy ETF股价,YieldMax MRNA Option Income Strategy ETF股市,YieldMax MRNA Option Income Strategy ETF股票价格,YieldMax MRNA Option Income Strategy ETF股票交易,YieldMax MRNA Option Income Strategy ETF股票购买,YieldMax MRNA Option Income Strategy ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"YieldMax MRNA Option Income Strategy ETF(MRNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest YieldMax MRNA Option Income Strategy ETF(MRNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}